-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $500

Benzinga·10/30/2026 15:22:04
Listen to the news
Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $440 to $500.